MoonLake Reports $68.9 Million in Q3 R&D Expenses, Reiterates Mid-2028 Runway

The Tip Desk · November 11, 2026 · 3 min read

Third-quarter 2026 research and development expenses rose to $68.9 million from $50.2 million in the prior quarter. Cash, cash equivalents and short-term marketable debt securities stood at $498.5 million as of September 30, 2026, with a runway the company expects to last to mid-2028.

MoonLake Immunotherapeutics (MLTX) reported third-quarter 2026 research and development expenses of $68.9 million, compared with $50.2 million in the prior quarter. The increase primarily reflected accrued milestone license fees associated with expected acceptance of its Biologics License Application. The clinical-stage biotechnology company focused on inflammatory diseases submitted a Biologics License Application on September 30, 2026, seeking U.S. approval of sonelokimab for moderate-to-severe hidradenitis suppurativa in adults and adolescents 12 and older.

The filing marked the step the company had planned after a positive final pre-BLA meeting in April, when it and the FDA aligned on submission plans and the label strategy, including adolescent data. MoonLake notified the FDA of its intent to apply for Priority Review. MoonLake said it expects FDA notification on whether the BLA is accepted for review within about 60 days of submission and a planned review timeline within about 74 days, with a decision on acceptance expected by the end of November 2026 and a PDUFA date and Priority Review decision by mid-December. A mid-cycle review is expected in the first half of 2027, and the company now expects a U.S. commercial launch in the second half of 2027 if approved.

The BLA is supported by the MIRA and VELA programs, including VELA-TEEN. MoonLake expects to complete VELA-TEEN in the fourth quarter of 2026 and to present final results at a scientific conference in the first quarter of 2027. It said it is continuing preparations for a potential U.S. launch, including market access, medical affairs, patient engagement and commercial infrastructure.

Research and development expenses were $68.9 million for the three months ended September 30, 2026, compared with $50.2 million for the three months ended June 30, 2026. The company attributed the $18.7 million increase primarily to accrued milestone license fees for a regulatory milestone associated with expected acceptance of the HS BLA. General and administrative expenses were $11.0 million, compared with $11.4 million in the prior quarter.

Cash, cash equivalents and short-term marketable debt securities declined to $498.5 million as of September 30, 2026, from $537.0 million at the end of the second quarter. The company said it expects sufficient capital to fund operating expenses and capital expenditure to mid-2028, the same horizon it had already described after the second quarter. Up to $400 million in non-dilutive funds remain available through its Hercules Capital debt facility.

In psoriatic arthritis, MoonLake completed enrollment in the Phase 3 IZAR-2 trial in September 2026, after an August update that had said enrollment was expected to finish in the third quarter. Initial topline results are expected in the first quarter of 2027 under a predefined unblinding protocol. Week 16 results from IZAR-1, announced in August, had already met all clinical endpoints for sonelokimab 60 mg with induction, including a 42.1% ACR50 response among biologic-naïve patients. Week 52 topline results from IZAR-1 are expected in the second quarter of 2027. P-OLARIS results are expected in early 2027.

The Phase 3 NOVA trial in palmoplantar pustulosis is on track to start enrollment in November 2026. Chief Financial Officer Matthias Bodenstedt said the quarter reflected execution across regulatory and clinical priorities and that the financial position and projected cash runway into mid-2028 position the company to prepare for the expected U.S. launch of sonelokimab next year.